Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-analyses

Gastroenterology

Volumn 139, Issue 4, 2010, Pages

  Woo, Gloria ^a,b   Tomlinson, George ^a,b,c   Nishikawa, Yasunori ^a   Kowgier, Matthew ^a   Sherman, Morris ^b,c   Wong, David K H ^b,c   Pham, Ba ^a,b   Ungar, Wendy J ^a,b,d   Einarson, Thomas R ^a,b   Heathcote, E Jenny ^b,c   Krahn, Murray ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Bayesian Direct and Indirect Comparison; Hepatitis B Virus (HBV); Meta analysis; Mixed Treatment Comparison (MTC)

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PLACEBO; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ADENINE; GUANINE; PHOSPHONIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BAYESIAN LEARNING; CHRONIC HEPATITIS; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEPATITIS B; HUMAN; LIVER HISTOLOGY; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; DRUG COMBINATION; HEPATITIS B, CHRONIC;

ADENINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; ORGANOPHOSPHONATES;

EID: 77957331059     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.06.042     Document Type: Article

References (42)

1. B.J. McMahon Epidemiology and natural history of hepatitis B Semin Liver Dis 25 Suppl 1 2005 3 8
2. G. Fattovich, F. Bortolotti, and F. Donato Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 2008 335 352
3. C.K. Hui, N. Leung, and T.W. Shek Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients Hepatology 46 2007 690 698
4. E.H. Buster, H.J. Flink, and Y. Cakaloglu Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 2008 459 467
5. D.E. Spackman, and D.L. Veenstra A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B Pharmacoeconomics 26 2008 937 949
6. M. Sherman, C. Yurdaydin, and H. Simsek Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks Hepatology 48 2008 99 108
7. A.S. Lok, and B.J. McMahon [AASLD practice guidelines. Chronic hepatitis B: update of therapeutic guidelines] Rom J Gastroenterol 13 2004 150 154
8. European Association for the Study of Liver EASL practice guidelines: management of chronic hepatitis B J Hepatol 50 2002 227 242
9. T.T. Chang, R.G. Gish, and R. de Man A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
10. C.L. Lai, D. Shouval, and A.S. Lok Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020
11. C.J. Chu, M. Hussain, and A.S. Lok Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection Hepatology 36 2002 1408 1415
12. F. Song, D.G. Altman, and A.M. Glenny Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses BMJ 326 2003 472
13. H.C. Bucher, G.H. Guyatt, and L.E. Griffith The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
14. A.E. Ades, M. Sculpher, and A. Sutton Bayesian methods for evidence synthesis in cost-effectiveness analysis Pharmacoeconomics 24 2006 1 19
15. S.G. Brooks Alternative methods for monitoring convergence of iterative simulations J Comput Graph Stat 7 1998 434 455
16. D.J. Spiegelhalter, K.R. Abrams, and J.P. Myles Bayesian approaches to clinical trials and health-care evaluations 2004 John Wiley and Sons Chichester
17. C.L. Lai, R.N. Chien, and N.W. Leung A one-year trial of lamivudine for chronic hepatitis B Asia Hepatitis Lamivudine Study Group N Engl J Med 339 1998 61 68
18. J.L. Dienstag, E.R. Schiff, and T.L. Wright Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
19. J.L. Dienstag, E.R. Schiff, and M. Mitchell Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy Hepatology 30 1999 1082 1087
20. P. Marcellin, T.T. Chang, and S.G. Lim Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816 (Pubitemid 36245757)
21. H.L. Chan, N.W. Leung, and A.Y. Hui A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone Ann Intern Med 142 2005 240 250
22. H.L. Janssen, M. van Zonneveld, and H. Senturk Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
23. C.L. Lai, N. Leung, and E.K. Teo A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B Gastroenterology 129 2005 528 536 (Pubitemid 41096641)
24. G.K. Lau, T. Piratvisuth, and K.X. Luo Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N Engl J Med 352 2005 2682 2695
25. H.L. Chan, E.J. Heathcote, and P. Marcellin Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial Ann Intern Med 147 2007 745 754
26. C.L. Lai, E. Gane, and Y.F. Liaw Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588
27. F.Y. Ren, D.M. Piao, and X.X. Piao A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B World J Gastroenterol 13 2007 4264 4267
28. J. Hou, Y.K. Yin, and D. Xu Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial Hepatology 47 2008 447 454
29. P. Marcellin, E.J. Heathcote, and M. Buti Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
30. J.J. Sung, J.Y. Lai, and S. Zeuzem Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatol 48 2008 728 735
31. S.J. Hadziyannis, N.C. Tassopoulos, and E.J. Heathcote Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
32. P. Marcellin, G.K. Lau, and F. Bonino Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N Engl J Med 351 2004 1206 1217
33. S. Kaymakoglu, D. Oguz, and G. Gur Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B Antimicrob Agents Chemother 51 2007 3020 3022 (Pubitemid 47206252)
34. P. Marcellin, E.J. Heathcote, and M. Buti Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
35. J.L. Dienstag, E. Schiff, and T.L. Wright Lamivudine as initial treatment for chronic hepatitis B in the United States NEJM 341 1999 1256 1263
36. A. Kau, J. Vermehren, and C. Sarrazin Treatment predictors of a sustained virologic response in hepatitis B and C J Hepatol 49 2008 634 651
37. Y.F. Liaw, J.J. Sung, and W.C. Chow Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
38. M.F. Yuen, D.K. Wong, and J. Fung HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 2008 1192 1199
39. H.I. Yang, S.N. Lu, and Y.F. Liaw Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 2002 168 174
40. C.J. Chen, H.I. Yang, and J. Su Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
41. N. Leung, C.Y. Peng, and H.W. Hann Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir Hepatology 49 2009 72 79
42. V.P. Papadopoulos, D.N. Chrysagis, and A.N. Protopapas Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study Med Sci Monit 15 2009 CR56 CR61